Share Email Print
cover

Proceedings Paper

Challenges facing academic research in commercializing event-detector implantable devices for an in-vivo biomedical subcutaneous device for biomedical analysis
Author(s): E. Juanola-Feliu; J. Colomer-Farrarons; P. Miribel-Català; J. Samitier; J. Valls-Pasola
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

It is widely recognized that the welfare of the most advanced economies is at risk, and that the only way to tackle this situation is by controlling the knowledge economies and dealing with. To achieve this ambitious goal, we need to improve the performance of each dimension in the "knowledge triangle": education, research and innovation. Indeed, recent findings point to the importance of strategies of adding-value and marketing during R+D processes so as to bridge the gap between the laboratory and the market and so ensure the successful commercialization of new technology-based products. Moreover, in a global economy in which conventional manufacturing is dominated by developing economies, the future of industry in the most advanced economies must rely on its ability to innovate in those high-tech activities that can offer a differential added-value, rather than on improving existing technologies and products. It seems quite clear, therefore, that the combination of health (medicine) and nanotechnology in a new biomedical device is very capable of meeting these requisites. This work propose a generic CMOS Front-End Self-Powered In-Vivo Implantable Biomedical Device, based on a threeelectrode amperometric biosensor approach, capable of detecting threshold values for targeted concentrations of pathogens, ions, oxygen concentration, etc. Given the speed with which diabetes can spread, as diabetes is the fastest growing disease in the world, the nano-enabled implantable device for in-vivo biomedical analysis needs to be introduced into the global diabetes care devices market. In the case of glucose monitoring, the detection of a threshold decrease in the glucose level it is mandatory to avoid critic situations like the hypoglycemia. Although the case study reported in this paper is complex because it involves multiple organizations and sources of data, it contributes to extend experience to the best practices and models on nanotechnology applications and commercialization.

Paper Details

Date Published: 3 May 2011
PDF: 10 pages
Proc. SPIE 8067, VLSI Circuits and Systems V, 80670P (3 May 2011); doi: 10.1117/12.886529
Show Author Affiliations
E. Juanola-Feliu, Univ. de Barcelona (Spain)
J. Colomer-Farrarons, Univ. de Barcelona (Spain)
P. Miribel-Català, Univ. de Barcelona (Spain)
J. Samitier, Univ. de Barcelona (Spain)
Institute for Bioengineering of Catalonia (Spain)
Biomedical Research Networking Ctr. in Bioengineering, Biomaterials and Nanomedicine (Spain)
J. Valls-Pasola, Univ. de Barcelona (Spain)


Published in SPIE Proceedings Vol. 8067:
VLSI Circuits and Systems V
Teresa Riesgo; Eduardo de la Torre-Arnanz, Editor(s)

© SPIE. Terms of Use
Back to Top